Oncology Peer Review On-The-Go: Matthew Allaway, DO, on Transperineal Biopsy Approach for Prostate Cancer
Matthew Allaway, DO, spoke with CancerNetwork® about a new transperineal biopsy approach to detect cancer in hard-to-reach areas of the prostate.
CancerNetwork® spoke with Matthew Allaway, DO, founder and chief executive officer at Perineologic, about a new prostate cancer biopsy technique that uses a transperineal approach to detect cancer in harder to reach areas of the prostate.
Allaway touched on the American Cancer Society’s annual report, “Cancer Facts & Figures 2022,” which indicated the rate of advanced-stage prostate cancer cases have increased in recent years. He also detailed a companion study to the report, and walked through the specific details and benefits of this biopsy technique.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Reference
Cancer Facts & Figures 2022. American Cancer Society. 2022. Accessed January 28, 2022. https://tinyurl.com/5rdc6nbc
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
